Compare SFBS & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBS | ADMA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2014 | 2012 |
| Metric | SFBS | ADMA |
|---|---|---|
| Price | $73.55 | $9.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $87.50 | $32.00 |
| AVG Volume (30 Days) | 333.2K | ★ 8.4M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 21.63 | N/A |
| EPS | ★ 5.06 | 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $32.30 | $27.46 |
| Revenue Next Year | $10.30 | $22.11 |
| P/E Ratio | ★ $14.38 | $15.00 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $66.48 | $7.21 |
| 52 Week High | $90.64 | $25.67 |
| Indicator | SFBS | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 24.21 |
| Support Level | $71.24 | N/A |
| Resistance Level | $76.42 | $16.44 |
| Average True Range (ATR) | 1.92 | 1.12 |
| MACD | 0.23 | -0.53 |
| Stochastic Oscillator | 51.93 | 20.60 |
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary. Through the subsidiary, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.